FoodMarble AIRE 2 Breath Tester - image 1

FoodMarble

FoodMarble AIRE 2 Breath Tester

Moderate (validated in research)
3.5/5
$249 (device) + $49 (food intolerance kit)

Where to Buy

About This Product

The FoodMarble AIRE 2 is the world's first personal breath tester that measures both hydrogen and methane in your breath, helping identify how your digestive system responds to different foods. The pocket-sized device connects to a smartphone app where you log meals and take breath tests to see fermentation levels in real-time. It comes with FODMAP test kits for fructose, lactose, sorbitol, and inulin to systematically identify your personal trigger foods. The device is reusable (no test strips to buy), rechargeable, and provides instant results. It was developed in collaboration with gastroenterologists and has been validated against clinical-grade hydrogen breath analyzers.

Why This Is Great for Thyroid Patients

Digestive issues affect the majority of hypothyroid patients — low stomach acid, slow motility, SIBO, and food sensitivities are all common. The AIRE 2 helps thyroid patients identify exactly which foods are causing bloating, gas, and discomfort, rather than relying on guesswork or overly restrictive elimination diets. The methane measurement is particularly valuable because methane-dominant SIBO (which causes constipation, a hallmark thyroid symptom) is often missed by standard hydrogen-only breath tests. For thyroid patients trying to optimize gut health to improve nutrient absorption and reduce autoimmune triggers, this device provides objective, personalized data.

Key Features

  • Hydrogen + methane dual sensors
  • Real-time breath analysis
  • Food intolerance testing (lactose, fructose, sorbitol, inulin)
  • Symptom tracking app

Selection Criteria

  • Clinically validated sensors
  • Used in research settings
  • Tracks treatment response
  • Identifies food triggers
  • Non-invasive

Evidence Level

Moderate (validated in research)

A growing body of research supports benefits for thyroid patients. More studies are underway.